

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

starting with: PYRIMIDIN\$(PYRIMIDINYL)ETHANE).CLM.

Search Results -

Terms	Documents
15 and pyrimidin\$.clm.	21

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

15 and pyrimidin\$.clm.

[Clear](#)**Search History****Today's Date: 10/12/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	15 and pyrimidin\$.clm.	21	<u>L10</u>
USPT	15 pyrimidin\$	60	<u>L9</u>
USPT	16 and 12.clm.	13	<u>L8</u>
USPT	16 and 12	57	<u>L7</u>
USPT	((514/378)!.CCLS.)	504	<u>L6</u>
USPT	14 and 12.ti.	90	<u>L5</u>
USPT	13 and 12.clm.	249	<u>L4</u>
USPT	12 and 11	811	<u>L3</u>
USPT	antivir\$ or hiv or hepatitis or herpes\$	31713	<u>L2</u>
USPT	((514/256 514/257 514/258 514/259 514/260 514/261 514/262 514/263 514/264 514/265 514/266 514/267 514/268 514/269 514/270 514/271 514/272 514/273 514/274 514/275 514/276)!.CCLS.)	5499	<u>L1</u>

=> d hist

(FILE 'HOME' ENTERED AT 13:22:37 ON 12 OCT 2001)

FILE 'REGISTRY' ENTERED AT 13:22:50 ON 12 OCT 2001

L1	0 S HWA486
L2	1 S HWA 486
L3	0 S A771726
L4	0 S A 771726
L5	1 S 771726
L6	1 S L5
L7	0 S TRIFLUOROMETHYLPHENYL HYDROXYCROTONAMIDE
L8	3 S LEFLUNOMIDE

FILE 'CAPLUS, MEDLINE' ENTERED AT 13:29:00 ON 12 OCT 2001

L9	645 S L2
L10	253996 S HEPATITIS OR HERPES? OR HSV OR CMV OR RHINOVIR? OR MEALS
L11	19 S L10 AND L9
L12	17 DUPLICATE REMOVE L11 (2 DUPLICATES REMOVED)
L13	12 S TRIFLUOROMETHYLPHENYL (S) CYANO (S) HYDROXYCROTONAMIDE
L14	51 S A771726
L15	2 S L14 AND L10
L16	793 S LEFLUNOMIDE

=> s l16 and l10

L17	20 L16 AND L10
-----	----------------

=> s l17 not l11

L18	2 L17 NOT L11
-----	---------------

=> d ibib abs 1-2

=> d hist

(FILE 'HOME' ENTERED AT 13:22:37 ON 12 OCT 2001)

FILE 'REGISTRY' ENTERED AT 13:22:50 ON 12 OCT 2001

L1	0 S HWA486
L2	1 S HWA 486
L3	0 S A771726
L4	0 S A 771726
L5	1 S 771726
L6	1 S L5
L7	0 S TRIFLUOROMETHYLPHENYL HYDROXYCROTONAMIDE
L8	3 S LEFLUNOMIDE

FILE 'CAPLUS, MEDLINE' ENTERED AT 13:29:00 ON 12 OCT 2001

L9	645 S L2
L10	253996 S HEPATITIS OR HERPES? OR HSV OR CMV OR RHINOVIR? OR MEALS
L11	19 S L10 AND L9
L12	17 DUPLICATE REMOVE L11 (2 DUPLICATES REMOVED)
L13	12 S TRIFLUOROMETHYLPHENYL (S) CYANO (S) HYDROXYCROTONAMIDE
L14	51 S A771726
L15	2 S L14 AND L10
L16	793 S LEFLUNOMIDE

=> s l16 and l10

L17 20 L16 AND L10

=> s l17 not l11

L18 2 L17 NOT L11

=> d ibib abs 1-2

L11 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1990:418743 CAPLUS

DOCUMENT NUMBER: 113:18743

TITLE: Induction of **interleukin-1 .alpha.**
and **.beta.** gene transcription in mouse
peritoneal exudate cells after intraperitoneal
infection with **herpes** simplex virus-1

AUTHOR(S): Sprecher, E.; Becker, Y.

CORPORATE SOURCE: Fac. Med., Hebrew Univ., Jerusalem, 91010, Israel

SOURCE: Arch. Virol. (1990), 110(3-4), 259-69

CODEN: ARVIDF; ISSN: 0304-8608

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Macrophages have been shown to play a detg. role in the immune defense
against **herpes** simplex virus-1 (HIV-1) i.p. infection in the
mouse. In the present study, the effect of **HSV-1** infection on
interleukin-1 .alpha. and **.beta.** gene
transcription in peritoneal exudate cells was investigated. **HSV**
-1 infection induced **interleukin-1 .alpha.** and .
beta. gene transcription in these cells. Induction of the
interleukin-1 .beta. gene initiated 6 h
postinfection (p.i.) and terminated at 48 h p.i. In contrast,
interleukin-1 .alpha. RNA was detectable at high levels
at 6 h p.i. but not at 24 h p.i. Inactivation of virus prior to

infection

prevented **HSV-1**-induced IL-1 gene induction, indicating that
only infectious virus is able to stimulate IL-1 gene transcription.

These

findings are discussed in relation to the role of macrophages in the
immunol. mechanisms of defense against **HSV-1** infection.

L12 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:549085 CAPLUS

DOCUMENT NUMBER: 121:149085

TITLE: Use of leflunomide for the inhibition of interleukin 1.beta.

INVENTOR(S): Weithmann, Klaus Ulrich; Bartlett, Robert Ryder

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: Eur. Pat. Appl., 6 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 607775	A2	19940727	EP 1994-100013	19940103
EP 607775	A3	19940831		
EP 607775	B1	19981209		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE				
AT 174218	E	19981215	AT 1994-100013	19940103
ES 2124800	T3	19990216	ES 1994-100013	19940103
JP 06234635	A2	19940823	JP 1994-425	19940107
US 5556870	A	19960917	US 1995-411849	19950328
PRIORITY APPLN. INFO.:			DE 1993-4300277	19930108
			US 1994-177960	19940106

AB Leflunomide is useful for treatment of diseases in which interleukin 1.beta. is involved, e.g. septic shock, leukemia, **hepatitis**, excessive cartilage resorption, HIV or mycobacterial infections, Alzheimer's disease, meningitis, muscular atrophy, thrombosis, arteriosclerosis, hyperlipemia, and degenerative joint disease. Thus, synthesis and release of interleukin 1.beta. by human blood mononuclear cells, induced by lipopolysaccharide from Salmonella abortus-equi, was suppressed by 0.05-0.1 mM leflunomide.